psilocybin (COMP360) / Compass Pathways 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12345678910111213...1314»
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin. (Pubmed Central) -  Aug 2, 2020   
    We also describe a pilot-scale protocol for recombinant PsiK that yielded 150 mg enzyme in active and soluble form. Our work consolidates the simplicity of tryptamine chemistry with the specificity and selectivity of enzymatic catalysis and helps provide access to an important drug at potentially reasonable cost.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications. (Pubmed Central) -  Jul 24, 2020   
    A rapid review of qualitative and quantitative journal articles in four major databases was conducted in February to April, 2019, using the terms hallucinogens, psychedelic, "lysergic acid diethylamide," psilocybin, ayahuasca, music, and/or "music therapy." Of 406 articles retrieved, 10 were included (n = 180; 18-69 years old)...Music therapists could be involved in the psychedelic therapy research renaissance through assisting with research to optimize music-based protocols used. If psychedelics become approved medicines, music therapists may be involved in offering psychedelic therapy as part of therapeutic teams.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Psychedelics and Psychedelic-Assisted Psychotherapy. (Pubmed Central) -  Jul 21, 2020   
    Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxymethamphetamine," and "MDMA," in human subjects, published between 2007 and July 1, 2019...The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin. (Pubmed Central) -  Jul 21, 2020   
    Psilocin was subsequently phosphorylated directly with phosphorous oxychloride for the first time, avoiding a tedious and poor atom economy benzyl-protecting group strategy common to all previously described methods for producing psilocybin. In this report, the challenges encountered in a 100 g scale first-generation literature-based synthesis are highlighted, followed by a detailed description of the newly developed second-generation synthesis to provide over one kilogram of high-purity psilocybin under cGMP.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Review, Journal:  Classical psychedelics for the treatment of depression and anxiety: A systematic review. (Pubmed Central) -  Jul 16, 2020   
    In this report, the challenges encountered in a 100 g scale first-generation literature-based synthesis are highlighted, followed by a detailed description of the newly developed second-generation synthesis to provide over one kilogram of high-purity psilocybin under cGMP. Though further evidence is required, psychedelics appear to be effective in significantly reducing symptoms of depression and anxiety and are well-tolerated.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] Integrating Religious and Spiritual Resources in Rehabilitation () -  Jul 14, 2020 - Abstract #ACRM2020ACRM_99;    
    The presentation will further offer discussions about the appropriate application of religious and spiritual interventions to both religious and non-religious individuals, and particularly given the increasing number of individuals (i.e., ~25% of population) who report being spiritual but not religious (i.e., the nones, secular humanists, atheists/agnostics). The presentation will conclude with suggestions for innovative spiritual interventions to improve the health and outcomes of persons with disabilities, including entheogens (e.g., peyote, psilocybin) and novel technologies (e.g., transcranial magnetic stimulation).
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] BS.07 – Can we successfully re-medicalise the psychedelics? (Room 1) -  Jul 10, 2020 - Abstract #ECNP2020ECNP_266;    
    LSD and, later, synthetic psilocybin (originally extracted from mushrooms) were made available for use in psychiatry and used more widely than is now currently appreciated...Dr. Guy Goodwin has been interviewed by ECNP press officer Tom Parkhill about this session on psychedelics.
  • ||||||||||  ketamine / Generic mfg., psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] Psychedelics and neuroplasticity: molecular mechanisms underlying the long-term effects of LSD (Room 2) -  Jul 10, 2020 - Abstract #ECNP2020ECNP_225;    
    However, the LSD-induced head-twitch response typically associated with acute effects of serotonergic hallucinogens remained unaffected by the mutation. These findings suggest that the enduring facilitation of fear extinction produced by psychedelics is dependent on TRKB, which reinforces the notion of a common mechanism for antidepressant-mediated plasticity.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] CA.08 – Banning psychedelics: the worst censorship of scientific research ever? (Room 2) -  Jul 10, 2020 - Abstract #ECNP2020ECNP_217;    
    He will explore how this field is now changing with new brain imaging studies revealing novel mechanisms of action and early clinical research into the benefits of psilocybin and depression and MDMA in trauma disorders and alcoholism...Registration is on a ‘first-come-first-served’ basis. For any participant above the 30 limit it will be possible to view the session.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] Micro-dosing with psychedelics to enhance mood and performance: anecdotes or scientific evidence? (Room 4) -  Jul 10, 2020 - Abstract #ECNP2020ECNP_197;    
    It is the practice of taking repeatedly small doses of substances like LSD and psilocybin, for a certain period which can be a few weeks, up to months and years...In the future, placebo-controlled studies will provide more clarity for who (age, diagnosis) microdosing can be effective and for which (cognitive, emotional) processes. The purpose of this presentation will be to give an overview of the knowledge we have so far about microdosing with psychedelics, and to identify which unanswered questions still exist.